Fig. 6: Immunotherapy cohorts analysis using scDist.
From: Robust identification of perturbed cell types in single-cell RNA-seq data
A Study design: discovery cohorts of four scRNA cohorts (cited in order as shown2,23,24,25) identify cell-type-specific differences and a differential gene signature between responders and non-responders. This signature was evaluated in validation cohorts of six bulk RNA-seq cohorts (cited in order as shown32,33,34,35,36,37,38). B Pre-treatment and post-treatment sample differences were estimated using Augur and scDist (Spearman correlation is reported on the plot). The error bars represent 95% confidence interval for the fitted linear regression line. C Significance of the estimated differences (scDist). D Kaplan–Meier plots display the survival differences in anti-PD-1 therapy patients, categorized by low-risk and high-risk groups using the median value of the NK-2 signature value; overall and progression-free survival is shown. E NK-2 signature levels in non-responders, partial-responders, and responders (Bulk RNA-seq cohorts). The boxplots report the median and first/third quartiles. A created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.
